`Seeing through a glass darkly': casting light on imidazoline `I' sites

Author： Eglen R.M.   Hudson A.L.   Kendall D.A.   Nutt D.J.   Morgan N.G.   Wilson V.G.   Dillon M.P.  

Publisher： Elsevier

ISSN： 0165-6147

Source： Trends in Pharmacological Sciences, Vol.19, Iss.9, 1998-09, pp. : 381-390

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I 1 and I 2 binding sites

By Coupry I.   Armsby C.C.   Alper S.L.   Brugnara C.   Parini A.  

European Journal of Pharmacology, Vol. 295, Iss. 1, 1996-01 ,pp. : 109-112

Elsevier

Access to resources Recommend Favorite

Not Seeing the Light?

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 40, Iss. 3, 2010-09 ,pp. : 222-223

John Wiley & Sons Inc

Access to resources Recommend Favorite

1,5-Bis(4-amidinophenoxy)pentane (pentamidine) is a potent inhibitor of [ 3 H]idazoxan binding to imidazoline I 2 binding sites

By Wood D.H.   Hall J.E.   Rose B.G.   Tidwell R.R.  

European Journal of Pharmacology, Vol. 353, Iss. 1, 1998-07 ,pp. : 97-103

Elsevier

Access to resources Recommend Favorite

Region-dependent effects of acute and chronic tranylcypromine in vivo on [ 3 H]2-BFI binding to brain imidazoline I 2 sites

By MacInnes N.   Handley S.L.  

European Journal of Pharmacology, Vol. 428, Iss. 2, 2001-10 ,pp. : 221-225

Elsevier

Access to resources Recommend Favorite

Imidazoline binding sites in Huntington's and Parkinson's disease putamen

By Reynolds G.P.   Boulton R.M.   Pearson S.J.   Hudson A.L.   Nutt D.J.  

European Journal of Pharmacology, Vol. 301, Iss. 1, 1996-04 ,pp. : 19-21

Elsevier

Access to resources Recommend Favorite